KDR and neoplasm: Anlotinib is one of the oral multi-target TKIs with broad-spectrum anti-tumor activities in various solid tumors which could suppress tumor proliferation, migration and metastasis by blocking the VEGFR, platelet-derived growth factor receptor, fibroblast growth factor receptors and c-Kit [21,22].